NABRIVA THERAPEUTICS PLC
25-28 North Wall Quay, IFSC
Dublin 1, Ireland
October 28, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Nabriva Therapeutics plc |
| Registration Statement on Form S-1 | |
| File No. 333-260146 | |
| Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Nabriva Therapeutics plc (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-260146) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on November 1, 2021, or as soon thereafter as practicable.
| Very truly yours, | |
| NABRIVA THERAPEUTICS PLC | |
| By: | /s/ Theodore Schroeder | |
| Name: | Theodore Schroeder | |
| Title: | Chief Executive Officer |
| cc: | Brian A. Johnson |
| Wilmer Cutler Pickering Hale and Dorr LLP |
